ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the shareholder(s) and / or legal heir(s) of the registered shareholder(s) in English language newspaper - Business Standard on 4th October, 2019. Alembic Pharmaceuticals (547):Buy
The stock of Alembic Pharma, which has been trading in the band between 500 and 550 for the past three months, broke out of the range as the company ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Approval for Clobetasol Propionate Spray, 0.05%. Please find enclosed herewith our press release. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s). ALEMBIC PHARMACEUTICALS LTD. - 533573 - Closure of Trading Window
With reference to the captioned matter, this is to inform the exchange that in terms of the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company will remain closed from 1st October, 2019 till 48 hours after the declaration of the unaudited financial results for the quarter and half year ended 30th September, 2019. The date of the Board Meeting for considering the unaudited financial results for the quarter and half year ended 30th September, 2019, will be intimated in due course. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s). Alembic Pharmaceuticals Ltd - 533573 - Alembic Pharmaceuticals Limited Announces Completion Of USFDA Inspection At Aleor Dermaceuticals Limited
With reference to the captioned subject, this is to inform the exchange that Aleor Dermaceuticals Ltd. (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd. (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has completed United States Food and Drug Administration (USFDA) inspection at its formulation manufacturing facility located at Karakhadi, Gujarat, India; with one observation. The inspection was carried out from 16th September, 2019 to 20th September, 2019. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s) for the purpose of claiming those shares from the Investor Education and Protection Fund (IEPF). ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the shareholder(s) and / or legal heir(s) of the registered shareholder(s) in English language newspaper - Business Standard on 27th August, 2019. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Successful US FDA Inspection At Alembic Pharmaceuticals Bioequivalence Facility At Vadodara
This is to inform the exchange that the Company's Bioequivalence Facility located at Vadodara was inspected by US Food & Drug Administration (USFDA) between 12th August, 2019 to 16th August, 2019 and between 12th August, 2019 to 20th August, 2019 for a) Bioequivalence Bioanalytical; and b) Bioequivalence Clinical There were no 483s issued by USFDA at the end of the inspection. We request you to kindly take the same on record.